Table 1. Descriptive characteristics by locoregional recurrence status, including women with a primary diagnosis between the years of 1975 and 2007.
| Locoregional recurrences (N=552) | No locoregional recurrences (N=4502) | |
|---|---|---|
| N(%) | N(%) | |
|
Age at diagnosis (years) | ||
| ⩽49 | 163 (31.59) | 1206 (29.20) |
| 50–59 | 156 (30.23) | 1079 (26.13) |
| 60–69 | 96 (18.60) | 1019 (24.67) |
| ⩾70 | 101 (19.57) | 826 (20.00) |
|
Mean follow-up (years) | ||
| Time from primary to death (s.d.) | 10.35 (7.50) | 12.16 (8.57) |
|
Tumour side | ||
| Left | 260 (47.10) | 2267 (50.63) |
| Right | 253 (45.83) | 2094 (46.51) |
| Unknown | 39 (7.07) | 141 (3.13) |
|
Menopausal status | ||
| Pre | 200 (36.23) | 1415 (31.43) |
| Peri | 56 (10.14) | 288 (6.40) |
| Post | 296 (53.62) | 2799 (62.17) |
|
Family history | ||
| First degree | 57 (10.33) | 518 (11.51) |
| Second degree | 38 (6.88) | 306 (6.80) |
| None | 417 (75.54) | 3092 (68.68) |
| First and second degree | 14 (2.54) | 93 (2.07) |
| Third degree | 0 (0.00) | 21 (0.47) |
| Missing | 26 (4.71) | 472 (10.48) |
|
No. of pregnancies | ||
| 0 | 105 (22.11) | 716 (22.16) |
| 1–2 | 212 (44.63) | 1395 (43.18) |
| 3–4 | 118 (24.84) | 855 (26.46) |
| >4 | 39 (8.21) | 243 (7.52) |
| Missing | 1 (0.21) | 22 (0.68) |
|
Tumour size at diagnosis (cm) | ||
| <2 | 107 (19.38) | 1507 (33.47) |
| 2–3 | 144 (26.09) | 1122 (24.92) |
| >3 | 301 (54.53) | 1873 (41.60) |
|
Invasive grade | ||
| Grade 1 | 38 (6.70) | 622 (13.43) |
| Grade 2 | 218 (38.45) | 1724 (37.22) |
| Grade 3 | 202 (35.63) | 1470 (31.74) |
| Missing | 109 (11.78) | 816 (17.62) |
|
Invasive type | ||
| Ductal not otherwise specified | 434 (78.62) | 3580 (79.52) |
| Lobular | 67 (12.14) | 456 (10.13) |
| Other | 5 (0.91) | 72 (1.60) |
| Missing | 46 (8.33) | 394 (8.75) |
|
Oestrogen receptor status | ||
| Negative | 171 (30.98) | 1052 (23.37) |
| Positive | 330 (59.78) | 3029 (67.28) |
| Missing | 51 (9.24) | 421 (9.35) |
|
Progesterone receptor status | ||
| Negative | 259 (46.92) | 1709 (37.96) |
| Positive | 230 (41.67) | 2318 (51.49) |
| Missing | 63 (11.41) | 475 (10.55) |
|
HER2 status | ||
| Negative | 223 (40.40) | 1970 (43.76) |
| Positive | 70 (12.68) | 525 (11.66) |
| Missing | 259 (46.92) | 2007 (44.58) |
|
Operation type | ||
| Mastectomy | 249 (45.11) | 2487 (55.24) |
| Breast conservation | 302 (54.71) | 2011 (44.67) |
| Other surgery | 1 (0.18) | 4 (0.09) |
|
Chemotherapy | ||
| No | 438 (79.35) | 3446 (76.54) |
| Yes | 114 (20.65) | 1056 (23.46) |
|
Radiotherapy | ||
| No | 299 (54.17) | 2449 (54.40) |
| Yes | 253 (45.83) | 2053 (45.60) |
|
Endocrine therapy | ||
| No | 370 (67.03) | 2599 (57.73) |
| Yes | 182 (32.97) | 1903 (42.27) |
|
No. of examined lymph nodes | ||
| Mean (s.d.) | 25.14 (8.71) | 23.76 (8.99) |
|
No. of positive lymph nodes | ||
| 0 | 165 (29.89) | 2076 (46.11) |
| 1–3 | 153 (27.72) | 1204 (26.74) |
| 4–10 | 68 (12.32) | 383 (8.51) |
| >10 | 81 (14.67) | 255 (5.66) |
| Missing | 85 (15.40) | 584 (19.97) |
|
BC-specific death | ||
| Noa | 190 (34.42) | 3422 (76.01) |
| Yes | 362 (65.58) | 1080 (23.99) |
Abbreviation: BC=breast cancer.
a
Including 242 for whom cause of death was unknown.